Mirum Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:08D Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
18 Sep 24	Buy€3,869	Frazier Life Sciences Management, LP	Company	115	€33.64
06 Sep 24	Buy€8,612	Frazier Life Sciences Management, LP	Company	230	€37.45
27 Mar 24	Buy€45,840	Eric Bjerkholt	Individual	2,000	€22.92
25 Mar 24	Sell€102,458	Peter Radovich	Individual	4,303	€23.81
18 Mar 24	Buy€47,462	Eric Bjerkholt	Individual	2,000	€23.73
02 Feb 24	Sell€145,947	Christopher Peetz	Individual	6,013	€24.27
02 Feb 24	Sell€29,466	Pamela Vig	Individual	1,214	€24.27
02 Feb 24	Sell€43,447	Peter Radovich	Individual	1,790	€24.27
02 Feb 24	Sell€20,558	Lara Longpre	Individual	847	€24.27
08 Jan 24	Sell€133,066	Christopher Peetz	Individual	5,209	€25.55
08 Jan 24	Sell€35,967	Pamela Vig	Individual	1,408	€25.54
08 Jan 24	Sell€35,967	Peter Radovich	Individual	1,408	€25.55
08 Jan 24	Sell€26,031	Lara Longpre	Individual	1,019	€25.55

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 08D?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	832,904	1.5%
Hedge Funds	3,075,907	5.53%
VC/PE Firms	6,570,392	11.8%
Institutions	45,120,844	81.2%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3%.

Top Shareholders

Top 25 shareholders own 86.47% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
13.7%	Frazier Life Sciences Management, LP	6,570,392	€259.0m	1.15%	10.53%
9.33%	Janus Henderson Group plc	4,480,284	€176.6m	-10.2%	0.08%
7.18%	Eventide Asset Management, LLC	3,445,363	€135.8m	-4.69%	2.5%
7.02%	BlackRock, Inc.	3,368,157	€132.8m	4.02%	no data
6.41%	BVF Partners L.P.	3,075,907	€121.2m	-29.6%	4.01%
5.2%	The Vanguard Group, Inc.	2,496,112	€98.4m	2.02%	no data
3.74%	State Street Global Advisors, Inc.	1,793,728	€70.7m	19.9%	no data
3.29%	Rock Springs Capital Management LP	1,580,488	€62.3m	-10.8%	2.26%
3.12%	Novo Holdings A/S	1,500,000	€59.1m	0%	0.04%
2.9%	Citadel Advisors LLC	1,391,409	€54.8m	-12.3%	0.06%
2.68%	Tang Capital Management, LLC	1,287,107	€50.7m	0%	3.94%
2.67%	T. Rowe Price Group, Inc.	1,284,106	€50.6m	7.08%	no data
1.95%	Geode Capital Management, LLC	936,197	€36.9m	3.2%	no data
1.87%	Pictet Asset Management Limited	895,690	€35.3m	2.35%	0.03%
1.85%	ClearBridge Investments, LLC	889,100	€35.0m	27%	0.03%
1.65%	Medical Strategy GmbH, Asset Management Arm	794,125	€31.3m	0%	2.01%
1.54%	Lord, Abbett & Co. LLC	741,368	€29.2m	15,200%	0.09%
1.52%	Avidity Partners Management, L.P.	731,104	€28.8m	0%	1.74%
1.41%	Polar Capital Holdings Plc	675,000	€26.6m	-8.91%	0.1%
1.35%	First Turn Management, LLC	647,611	€25.5m	-7.93%	4.56%
1.28%	Norges Bank Investment Management	614,905	€24.2m	0%	no data
1.25%	Goldman Sachs Group, Investment Banking and Securities Investments	598,136	€23.6m	-17.7%	0.01%
1.23%	Franklin Resources, Inc.	589,967	€23.3m	-37.2%	0.01%
1.21%	Morgan Stanley, Investment Banking and Brokerage Investments	581,189	€22.9m	9.86%	no data
1.13%	Boone Capital Management LLC	543,843	€21.4m	3.85%	6.35%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/20 13:54
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mirum Pharmaceuticals, Inc. is covered by 14 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Brian Skorney	Baird
Joshua Schimmer	Cantor Fitzgerald & Co.
David Lebowitz	Citigroup Inc